247 related articles for article (PubMed ID: 17306893)
1. Modulation of L-DOPA-induced abnormal involuntary movements by clinically tested compounds: further validation of the rat dyskinesia model.
Dekundy A; Lundblad M; Danysz W; Cenci MA
Behav Brain Res; 2007 Apr; 179(1):76-89. PubMed ID: 17306893
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological validation of a mouse model of l-DOPA-induced dyskinesia.
Lundblad M; Usiello A; Carta M; Håkansson K; Fisone G; Cenci MA
Exp Neurol; 2005 Jul; 194(1):66-75. PubMed ID: 15899244
[TBL] [Abstract][Full Text] [Related]
3. The selective alpha1 adrenoceptor antagonist HEAT reduces L-DOPA-induced dyskinesia in a rat model of Parkinson's disease.
Buck K; Ferger B
Synapse; 2010 Feb; 64(2):117-26. PubMed ID: 19771592
[TBL] [Abstract][Full Text] [Related]
4. The partial 5-HT(1A) agonist buspirone reduces the expression and development of l-DOPA-induced dyskinesia in rats and improves l-DOPA efficacy.
Eskow KL; Gupta V; Alam S; Park JY; Bishop C
Pharmacol Biochem Behav; 2007; 87(3):306-14. PubMed ID: 17553556
[TBL] [Abstract][Full Text] [Related]
5. A simple rodent assay for the in vivo identification of agents with potential to reduce levodopa-induced dyskinesia in Parkinson's disease.
Johnston TH; Lee J; Gomez-Ramirez J; Fox SH; Brotchie JM
Exp Neurol; 2005 Feb; 191(2):243-50. PubMed ID: 15649479
[TBL] [Abstract][Full Text] [Related]
6. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia.
Muñoz A; Li Q; Gardoni F; Marcello E; Qin C; Carlsson T; Kirik D; Di Luca M; Björklund A; Bezard E; Carta M
Brain; 2008 Dec; 131(Pt 12):3380-94. PubMed ID: 18952677
[TBL] [Abstract][Full Text] [Related]
7. BN82451 attenuates L-dopa-induced dyskinesia in 6-OHDA-lesioned rat model of Parkinson's disease.
Spinnewyn B; Mautino G; Marin JG; Rocher MN; Grandoulier AS; Ferrandis E; Auguet M; Chabrier PE
Neuropharmacology; 2011 Mar; 60(4):692-700. PubMed ID: 21129389
[TBL] [Abstract][Full Text] [Related]
8. 5-Hydroxy-tryptophan for the treatment of L-DOPA-induced dyskinesia in the rat Parkinson's disease model.
Tronci E; Lisci C; Stancampiano R; Fidalgo C; Collu M; Devoto P; Carta M
Neurobiol Dis; 2013 Dec; 60():108-14. PubMed ID: 24004632
[TBL] [Abstract][Full Text] [Related]
9. An improved model to investigate the efficacy of antidyskinetic agents in hemiparkinsonian rats.
Spinnewyn B; Charnet C; Cornet S; Roubert V; Chabrier PE; Auguet M
Fundam Clin Pharmacol; 2011 Oct; 25(5):608-18. PubMed ID: 21077938
[TBL] [Abstract][Full Text] [Related]
10. The selective D(3) receptor antagonist, S33084, improves parkinsonian-like motor dysfunction but does not affect L-DOPA-induced dyskinesia in 6-hydroxydopamine hemi-lesioned rats.
Mela F; Millan MJ; Brocco M; Morari M
Neuropharmacology; 2010 Feb; 58(2):528-36. PubMed ID: 19733554
[TBL] [Abstract][Full Text] [Related]
11. MDMA and fenfluramine reduce L-DOPA-induced dyskinesia via indirect 5-HT1A receptor stimulation.
Bishop C; Taylor JL; Kuhn DM; Eskow KL; Park JY; Walker PD
Eur J Neurosci; 2006 May; 23(10):2669-76. PubMed ID: 16817869
[TBL] [Abstract][Full Text] [Related]
12. Modulating mGluR5 and 5-HT1A/1B receptors to treat l-DOPA-induced dyskinesia: effects of combined treatment and possible mechanisms of action.
Iderberg H; Rylander D; Bimpisidis Z; Cenci MA
Exp Neurol; 2013 Dec; 250():116-24. PubMed ID: 24029003
[TBL] [Abstract][Full Text] [Related]
13. Transcription factors involved in the pathogenesis of L-DOPA-induced dyskinesia in a rat model of Parkinson's disease.
Cenci MA
Amino Acids; 2002; 23(1-3):105-9. PubMed ID: 12373525
[TBL] [Abstract][Full Text] [Related]
14. Antagonism of metabotropic glutamate receptor type 5 attenuates l-DOPA-induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson's disease.
Mela F; Marti M; Dekundy A; Danysz W; Morari M; Cenci MA
J Neurochem; 2007 Apr; 101(2):483-97. PubMed ID: 17359492
[TBL] [Abstract][Full Text] [Related]
15. Chronic SKF83959 induced less severe dyskinesia and attenuated L-DOPA-induced dyskinesia in 6-OHDA-lesioned rat model of Parkinson's disease.
Zhang H; Ma L; Wang F; Chen J; Zhen X
Neuropharmacology; 2007 Jul; 53(1):125-33. PubMed ID: 17553535
[TBL] [Abstract][Full Text] [Related]
16. Oral creatine supplementation attenuates L-DOPA-induced dyskinesia in 6-hydroxydopamine-lesioned rats.
Valastro B; Dekundy A; Danysz W; Quack G
Behav Brain Res; 2009 Jan; 197(1):90-6. PubMed ID: 18762218
[TBL] [Abstract][Full Text] [Related]
17. Study of the antidyskinetic effect of eltoprazine in animal models of levodopa-induced dyskinesia.
Bezard E; Tronci E; Pioli EY; Li Q; Porras G; Björklund A; Carta M
Mov Disord; 2013 Jul; 28(8):1088-96. PubMed ID: 23389842
[TBL] [Abstract][Full Text] [Related]
18. The NK1 receptor antagonist N-acetyl-L-tryptophan reduces dyskinesia in a hemi-parkinsonian rodent model.
Thornton E; Hassall MM; Corrigan F; Vink R
Parkinsonism Relat Disord; 2014 May; 20(5):508-13. PubMed ID: 24637127
[TBL] [Abstract][Full Text] [Related]
19. Synergistic antidyskinetic effects of topiramate and amantadine in animal models of Parkinson's disease.
Kobylecki C; Hill MP; Crossman AR; Ravenscroft P
Mov Disord; 2011 Nov; 26(13):2354-63. PubMed ID: 21953539
[TBL] [Abstract][Full Text] [Related]
20. Low doses of sarizotan reduce dyskinesias and maintain antiparkinsonian efficacy of L-Dopa in parkinsonian monkeys.
Grégoire L; Samadi P; Graham J; Bédard PJ; Bartoszyk GD; Di Paolo T
Parkinsonism Relat Disord; 2009 Jul; 15(6):445-52. PubMed ID: 19196540
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
